Depleting Disease, Empowering Health

Our Mission

We are committed to delivering breakthrough therapies for autoimmune disease by combining scientific rigor and deep compassion – bringing hope and healing to patients who need it most.

Our Leadership

Scott Requadt, CEO Salim Mujais, CMO Niki Bili, VP, Clinical Development Bob Huang, VP, CMC & Manufacturing

Prolium is a small but dedicated team leveraging big science to better the lives of people with severe autoimmune disorders.

Meet the Full Team →

Recent News

Mar 3, 2026 Prolium Bioscience Launches with $50 Million and Announces First Patients Dosed with PRO-203, a Potential Best-in-Class CD20xCD3 T-Cell Engager, for Severe Autoimmune Disease
Contact Prolium